Skip to main content

Table 3 Multivariate survival analysis of LINE-1 methylation level and clinicopathological parameters with respect to overall survival

From: Tumoral LINE-1 hypomethylation is associated with poor survival of patients with intrahepatic cholangiocarcinoma

 

Hazard ratio (95% C.I.)

P-value

Hazard ratio (95% C.I.)

P-value

LINE-1 methylation levela

Q3, Q4 (n = 86)

    

Q1, Q2 (n = 86)

2.643 (1.443–4.482)

0.002

2.248 (1.205–4.196)

0.011

N staging

pN0 (n = 133)

    

pN1 (n = 39)

2.211 (1.176–4.157)

0.014

2.749 (1.491–5.066)

0.001

T staging

  

0.025

 

0.130

pT1 (n = 48)

Reference

 

Reference

 

pT2 (n = 52)

1.943 (0.979–3.855)

0.058

0.555 (0.211–1.458)

0.232

pT3 (n = 47)

0.941 (0.420–2.105)

0.882

0.363 (0.121–1.091)

0.071

pT4 (n = 25)

0.433 (0.123–1.523)

0.192

0.216 (0.053–0.889)

0.034

Gross type

  

0.076

 

0.064

Mass forming (n = 141)

Reference

 

Reference

 

Periductal infiltrative (n = 8)

0

0.964

0

0.972

Intraductal growth (n = 18)

0.134 (0.018–0.971)

0.047

0.123 (0.017–0.910)

0.040

Mixed (n = 5)

2.672 (0.827–8.638)

0.101

2.878 (0.854–9.694)

0.088

Lymphatic emboli

Absent (n = 102)

    

Present (n = 70)

2.519 (1.429–4.438)

0.001

2.720 (1.168–6.337)

0.020

Perineural invasion

Absent (n = 118)

    

Present (n = 54)

0.386 (0.181–0.822)

0.014

0.373 (0.162–0.860)

0.021

Differentiation

  

0.083

 

0.638

Well (n = 23)

Reference

   

Moderate (n = 94)

9.405 (1.283–68.943)

0.027

  

Poor (n = 55)

9.671 (1.290–72.518)

0.027

  
  1. aRegardless of whether adjuvant and/or neoadjuvant therapy was included or not in the multivariate analysis, the hazard ratio of LINE-1 methylation level did not change